(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 35.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Ascendis Pharma A's revenue in 2026 is $1,018,564,705.On average, 19 Wall Street analysts forecast ASND's revenue for 2026 to be $84,906,550,365, with the lowest ASND revenue forecast at $77,825,828,535, and the highest ASND revenue forecast at $96,148,749,060. On average, 19 Wall Street analysts forecast ASND's revenue for 2027 to be $124,285,301,595, with the lowest ASND revenue forecast at $106,024,492,665, and the highest ASND revenue forecast at $149,875,278,735.
In 2028, ASND is forecast to generate $154,098,867,195 in revenue, with the lowest revenue forecast at $126,272,872,635 and the highest revenue forecast at $179,875,179,120.